We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Aptamer Group

Aptamer Group is a leading provider of Optimer® binders for use in therapeutics, diagnostics, bioprocessing and research. The Company strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer® technology.

Latest Content

Two scientists collaborating in a lab using digital tools for drug discovery research.

Aptamer Expands Into Targeted Radiopharmaceuticals With Major Top 3 Pharma Contract

Aptamer inks £360K deal with a top pharma to develop Optimer® radiopharmaceuticals targeting cancer.

Medical illustration of human kidneys highlighting nephropathy and potential treatments.

Aptamer Signs Therapeutic Development Agreement With Invizius

Aptamer Group has signed a development agreement with Invizius to create Optimer^® binders targeting the complement system, implicated in autoimmune, fibrotic and inflammatory diseases.

Digital illustration promoting Aptamer’s innovative biomarker discovery service for drug and diagnostic research.

Aptamer Group^® Introduces Novel Biomarker Discovery Service

Aptamer Group unveils Optimer-based biomarker discovery service, enabling faster disease marker identification and validation.

Gloved hand holding test tube near DNA model representing gene therapy research.

Aptamer Group Identifies Novel Target To Enable Cell-Specific Gene Therapy for Liver Fibrosis

Aptamer validates targeted RNA delivery to liver fibrosis cells using its Optimer platform and a novel HSC marker.

Gloved hand holding test tube near DNA helix, symbolizing gene therapy research.

Aptamer Announces New Data at ASGCT

Aptamer Group presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis, showing its potential for broad applicability in fibrotic diseases at the ASGCT 2025 Annual Meeting.

Scientists conducting research in a modern lab.

Optimer Licensing Agreements and Repeat Custom

Aptamer Group has secured two new development contracts and a licensing agreement to expand its Optimer platform’s applications in enzyme modulation and small molecule recognition.

Multiple brain scan MRI images showing cross-sectional views of the human brain.

Aptamer Group and Neuro-Bio Advance Alzheimer’s Test and Agree Royalties

Aptamer Group plc is pleased to announce the successful adaptation of the Optimer-based test for Alzheimer’s disease into an Enzyme-Linked Immunosorbent Assay (ELISA).

Gloved hand holding three syringes, representing Optimer binders used as vaccine adjuvants.

Licensing Agreed for Optimer As Novel Vaccine Adjuvant

Aptamer licenses Optimers to the University of Glasgow for use in swine vaccines, targeting global animal health markets.

Two scientists looking at a laptop screen.

New Optimer Contract To Develop Bioanalytical Tools for RNA Therapy

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the signing of a new development contract with a rare disease biopharmaceutical company.

Cells.

New Scientific Advisory Board Members

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce three new members to its Scientific Advisory Board (SAB).

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter